Ryan Moy: Wrote this IIT with Yelena Y. Janjigian when I was a fellow and great to see this phase 2 study now completed.
Ryan Moy, Assistant Professor of Medicine and Medical Oncologist at Columbia University Irving Medical Center, recently shared a post by The Lancet Oncology on X/Twitter, adding:
“Wrote this IIT with Yelena Y. Janjigian when I was a fellow and great to see this phase 2 study now completed. FOLFOX plus regorafenib and nivolumab for advanced EG cancer. ORR 76% and 6-month PFS 71%. Nice work, Sam Cytryn and team!”
Quoting The Lancet Oncology’s post:
“NOW OF: A US single-arm, single-center, phase 2 trial assesses the safety and activity of regorafenib in combination with nivolumab and chemotherapy in the first-line treatment of advanced oesophagogastric adenocarcinoma.”
For the article click here.
Source: Ryan Moy/Twitter and The Lancet Oncology/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023